UTHR: Although bringing oral remodulin to the market seems more challenging now after the CRL, sounds like Dr Rothblatt insists on doing so. In addition to the problems you've mentioned, wouldn't an oral remodulin hurt Tyvaso market share if approved?
News 
Market Data 
Discover 
AI
